Please use this identifier to cite or link to this item:
Title: Exacerbations of severe asthma in patients treated with mepolizumab
Authors: Shrimanker, Rahul
Pavord, Ian D.
Yancey, Steve
Heaney, Liam G.
Green, Ruth H.
Bradding, Peter
Hargadon, Beverley
Brightling, Chris E.
Wardlaw, Andrew J.
Haldar, Pranabashis
First Published: 13-Dec-2018
Publisher: European Respiratory Society
Citation: European Respiratory Journal, 2018, 52: 1801127;
Abstract: Mepolizumab, a humanised monoclonal antibody that neutralises interleukin-5, reduces exacerbations of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD) [1, 2]. The beneficial effect of treatment is most obvious in patients with a raised peripheral blood eosinophil count, a group who are at high risk of exacerbation off treatment [2, 3]. Even in this population, exacerbation rates whilst receiving mepolizumab are around one per patient per year. The nature of these remaining exacerbations has not been described. We carried out a post hoc comparison of exacerbations occurring during treatment with mepolizumab or placebo in a previously reported, double-blind, placebo-controlled trial of mepolizumab in severe eosinophilic asthma [1]. We tested the hypothesis that exacerbations in each group differ with respect to change in symptom scores, forced expiratory volume in 1 s (FEV1) and inflammatory profile.
DOI Link: 10.1183/13993003.01127-2018
ISSN: 0903-1936
Embargo on file until: 13-Jun-2020
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2018, European Respiratory Society. Deposited with reference to the publisher’s open access archiving policy. (
Description: The file associated with this record is under embargo until 18 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
ERJ Mepo manuscript 10.18.pdfPost-review (final submitted author manuscript)192.12 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.